Replies to post #54377 on NanoViricides Inc. (NNVC)

[BonelessCat]

That's correct, the first of the patents held or applied for by TheraCour won't expire for another 10 years. Also, FDA approval for each specific indication that is deemed an orphan drug will carry an additional exclusive period of up to 5 years before a generic can come onto the market. In the meantime, the patent that applies directly to use as a viricidal agent was filed only 4 years ago, so has at least 12 more years to go.

[noretreat]

Some expirations begin in 2017, the key one goes away in 2020. After that, little tweaks can get around the subsequent patents, if any are granted. There is an application from 2006 that I don't see an approval for, but I haven't looked everywhere ... I will post what expires earlier as soon as I find it.

Patent or Application
Date of Issue/
Application US Expiry Date
International
Owners
US6,521,736 (Certain specific amphiphilic polymers).
Issued: Feb 18, 2003
Feb 18, 2020
N/A
TheraCour Pharma and Univ. of Massachusetts, Lowell. [Nonexclusive license from TheraCour Pharma].

Of the patents and technologies licensed, the Company believes that the Company will not be using the intellectual property, compositions of matter, or other aspects described and secured under the US Patent No. US 6,521,736. This patent, the Company believes, discloses prototype materials that served to establish the proof of principles of Dr. Anil Diwan, the Company’s President and co-founder whether such materials were possible to create and whether such materials would indeed be capable of encapsulation of pharmaceutically relevant compounds. The Company believes that the new and novel compositions disclosed in the new patent application, no. PCT/US06/01820, provide the necessary features that enable the development of nanoviricides. The Company believes that no other published literature materials or existing patents are capable of providing all of the necessary features for this development, to the best of our knowledge. However, the Company has no knowledge of the extensive active internal developments at a number of companies in the targeted therapeutics area.